Terence Flynn
Stock Analyst at Morgan Stanley
(3.97)
# 631
Out of 4,711 analysts
171
Total ratings
53.76%
Success rate
9.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Overweight | $231 → $224 | $175.58 | +27.58% | 13 | Nov 12, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Underweight | $36 → $39 | $57.33 | -31.97% | 10 | Nov 12, 2024 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $130 → $123 | $98.05 | +25.45% | 14 | Nov 1, 2024 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $169 → $175 | $144.47 | +21.13% | 18 | Oct 16, 2024 | |
| BNTX BioNTech SE | Upgrades: Overweight | $93 → $145 | $113.08 | +28.23% | 1 | Sep 24, 2024 | |
| GPCR Structure Therapeutics | Initiates: Overweight | $118 | $27.90 | +322.94% | 1 | Sep 23, 2024 | |
| LLY Eli Lilly | Reiterates: Overweight | $1,106 | $767.76 | +44.06% | 18 | Aug 27, 2024 | |
| BHVN Biohaven | Initiates: Overweight | $58 | $36.26 | +59.96% | 1 | Jul 24, 2024 | |
| ALMS Alumis | Initiates: Overweight | $36 | $8.82 | +308.16% | 1 | Jul 23, 2024 | |
| RPRX Royalty Pharma | Maintains: Overweight | $48 → $51 | $24.92 | +104.65% | 11 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $310 → $303 | $263.38 | +15.04% | 5 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $310 → $321 | $359.58 | -10.73% | 8 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $38 → $40 | $15.50 | +158.06% | 4 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $121 → $168 | $90.14 | +86.38% | 6 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $29 | $26.36 | +10.02% | 13 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $10 | $19.83 | -49.57% | 3 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $46 → $48 | $40.72 | +17.88% | 6 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $3.95 | +102.53% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $20 | $18.48 | +8.23% | 7 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $85 | $12.18 | +597.87% | 4 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $12 | $3.09 | +288.35% | 9 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $27 → $22 | $14.58 | +50.89% | 7 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $146.47 | +197.67% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $245.44 | - | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.40 | - | 1 | Jul 21, 2017 |
AbbVie
Nov 12, 2024
Maintains: Overweight
Price Target: $231 → $224
Current: $175.58
Upside: +27.58%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Underweight
Price Target: $36 → $39
Current: $57.33
Upside: -31.97%
Merck & Co.
Nov 1, 2024
Maintains: Equal-Weight
Price Target: $130 → $123
Current: $98.05
Upside: +25.45%
Johnson & Johnson
Oct 16, 2024
Maintains: Equal-Weight
Price Target: $169 → $175
Current: $144.47
Upside: +21.13%
BioNTech SE
Sep 24, 2024
Upgrades: Overweight
Price Target: $93 → $145
Current: $113.08
Upside: +28.23%
Structure Therapeutics
Sep 23, 2024
Initiates: Overweight
Price Target: $118
Current: $27.90
Upside: +322.94%
Eli Lilly
Aug 27, 2024
Reiterates: Overweight
Price Target: $1,106
Current: $767.76
Upside: +44.06%
Biohaven
Jul 24, 2024
Initiates: Overweight
Price Target: $58
Current: $36.26
Upside: +59.96%
Alumis
Jul 23, 2024
Initiates: Overweight
Price Target: $36
Current: $8.82
Upside: +308.16%
Royalty Pharma
Jul 11, 2024
Maintains: Overweight
Price Target: $48 → $51
Current: $24.92
Upside: +104.65%
Jul 11, 2024
Maintains: Equal-Weight
Price Target: $310 → $303
Current: $263.38
Upside: +15.04%
Jul 11, 2024
Downgrades: Equal-Weight
Price Target: $310 → $321
Current: $359.58
Upside: -10.73%
May 13, 2024
Maintains: Overweight
Price Target: $38 → $40
Current: $15.50
Upside: +158.06%
May 6, 2024
Maintains: Buy
Price Target: $121 → $168
Current: $90.14
Upside: +86.38%
May 2, 2024
Maintains: Equal-Weight
Price Target: $28 → $29
Current: $26.36
Upside: +10.02%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $9 → $10
Current: $19.83
Upside: -49.57%
Feb 26, 2024
Maintains: Underweight
Price Target: $46 → $48
Current: $40.72
Upside: +17.88%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $3.95
Upside: +102.53%
Nov 13, 2023
Maintains: Equal-Weight
Price Target: $32 → $20
Current: $18.48
Upside: +8.23%
Nov 13, 2023
Maintains: Overweight
Price Target: $90 → $85
Current: $12.18
Upside: +597.87%
Oct 11, 2023
Maintains: Equal-Weight
Price Target: $25 → $12
Current: $3.09
Upside: +288.35%
Oct 11, 2023
Maintains: Equal-Weight
Price Target: $27 → $22
Current: $14.58
Upside: +50.89%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $146.47
Upside: +197.67%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $245.44
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $0.40
Upside: -